- Home
- PCVX vs LEA Comparison
PCVX vs LEA Comparison
Compare PCVX & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | LEA |
|---|---|---|
| Founded | 2013 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.3B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PCVX | LEA |
|---|---|---|
| Price | $59.23 | $131.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $88.25 | ★ $132.21 |
| AVG Volume (30 Days) | ★ 927.4K | 508.6K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 7.13 |
| Revenue | N/A | ★ $23,259,100,000.00 |
| Revenue This Year | N/A | $2.50 |
| Revenue Next Year | N/A | $3.12 |
| P/E Ratio | ★ N/A | $17.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.81 | $96.04 |
| 52 Week High | $65.00 | $150.33 |
Technical Indicators
Market Signals| Indicator | PCVX | LEA |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 49.03 |
| Support Level | $58.51 | $126.85 |
| Resistance Level | $63.39 | $128.04 |
| Average True Range (ATR) | 2.10 | 3.20 |
| MACD | -0.39 | 0.84 |
| Stochastic Oscillator | 10.69 | 42.69 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.